What is the price target for HARP stock?
15 analysts have analysed HARP and the average price target is 24.14 USD. This implies a price increase of 4.93% is expected in the next year compared to the current price of 23.01.
HARPOON THERAPEUTICS INC (HARP) Forecast, Price Target & Analyst Ratings
NASDAQ:HARP • US41358P2056
Current stock price
23.01 USD
+0.02 (+0.09%)
At close:
23 USD
-0.01 (-0.04%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HARPOON THERAPEUTICS INC (HARP).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 25, 2024
- Period
- Q4 / 2023
- EPS Estimate
- -$0.65
- Revenue Estimate
- 5.715M
Price Target Details & History
Consensus Price Target and Range
Mean target
$24.14
Upside
+ 4.93%
From current price of $23.01 to mean target of $24.14, Based on 15 analyst forecasts
Low
$23.23
Median
$23.46
High
$28.35
Price Target Revisions
1 Month
5.58%
3 Months
57.81%
Price Target Summary
15 Wall Street analysts provided a forecast for the next 12 months for HARP. The average price target is 24.14 USD. This implies a price increase of 4.93% is expected in the next year compared to the current price of 23.01.
The average price target has been revised upward by 57.81% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
72.00%
HARP was analyzed by 15 analysts. The buy percentage consensus is at 72. So analysts seem to be have mildly positive about HARP.
In the previous month the buy percentage consensus was at a similar level.
HARP was analyzed by 15 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-03-26 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-02-26 | Citigroup | Downgrade | Buy -> Neutral |
| 2024-01-16 | TD Cowen | Downgrade | Outperform -> Market Perform |
| 2024-01-08 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-01-05 | Oppenheimer | Initiate | Outperform |
| 2023-12-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-20 | TD Cowen | Initiate | Outperform |
| 2023-10-24 | Citigroup | Maintains | Buy -> Buy |
| 2023-09-18 | Citigroup | Maintains | Buy -> Buy |
| 2023-09-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2023-09-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-04-03 | Canaccord Genuity | Maintains | Buy |
| 2023-03-29 | HC Wainwright & Co. | Maintains | Buy |
| 2022-12-14 | Truist Securities | Downgrade | Buy -> Hold |
| 2022-11-15 | SVB Leerink | Maintains | Outperform |
| 2022-11-15 | Baird | Downgrade | Outperform -> Neutral |
| 2022-08-29 | Citigroup | Maintains | Buy |
| 2022-08-23 | Truist Securities | Maintains | Buy |
| 2022-08-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-11 | SVB Leerink | Maintains | Outperform |
| 2022-08-11 | Piper Sandler | Maintains | Overweight |
| 2022-05-16 | Wedbush | Upgrade | Neutral -> Outperform |
| 2021-11-11 | SVB Leerink | Maintains | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 25, 2024
- Period
- Q4 / 2023
- EPS Estimate
- -$0.65
- Revenue Estimate
- 5.715M
- Revenue Q2Q
- 39.73%
- EPS Q2Q
- 88.18%
- Number of Analysts
- 10
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
6.92%
EPS (1 Month)
0.00%
EPS (3 Months)
-0.01%
Next Earnings Summary
HARP is expected to report earnings on 3/25/2024. The consensus EPS estimate for the next earnings is -0.65 USD and the consensus revenue estimate is 5.71M USD.
The next earnings revenue estimate has been revised upward by 6.92% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2023 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 17.44M 201.73% | 23.65M 35.61% | 31.92M 34.97% | 38.812M 21.59% | 21.078M -45.69% | 20.85M -1.08% | 47.521M 127.92% | 104.04M 118.93% | 162.53M 56.22% | 233.72M 43.80% | 310.33M 32.78% | |
| EBITDA YoY % growth | -49.25M 14.06% | -64.61M -31.19% | -65.97M -2.10% | -35.986M 45.45% | -74.193M -106.17% | -78.051M -5.20% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -51.33M 11.82% | -66.8M -30.14% | -68.33M -2.29% | -33.496M 50.98% | -62.422M -86.36% | -74.173M -18.83% | -80.78M -8.91% | -55.626M 31.14% | -5.56M 90.01% | 50.012M 999.53% | 117.06M 134.06% | |
| Operating Margin | -294.32% | -282.45% | -214.07% | -86.30% | -296.15% | -355.75% | -169.99% | -53.47% | -3.42% | 21.40% | 37.72% | |
| EPS YoY % growth | -2.00 24.24% | -2.06 -3.00% | -20.50 -895.15% | -2.04 90.06% | -3.73 -83.23% | -3.84 -2.91% | -1.09 71.66% | -0.38 64.87% | 0.58 252.00% | 1.28 119.74% | 2.39 86.83% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.65 88.18% | -0.83 73.13% | -1.26 -521.26% | -1.60 -248.80% | -5.00 -668.54% |
| Revenue Q2Q % growth | 5.715M 39.73% | 6.375M -25.70% | 6.375M -68.47% | 6.375M 43.26% | 6.375M 11.55% |
| EBITDA Q2Q % growth | -16.459M -0.66% | -17.176M -69.89% | -17.925M -441.44% | -19.13M -75.99% | N/A |
| EBIT Q2Q % growth | -11.409M 39.02% | -4.59M 57.38% | -9.69M -329.62% | -14.79M -21.83% | -32.13M -181.62% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
21.93%
EPS Next 5 Year
14.65%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-16.53%
Revenue Next 5 Year
23.74%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-5.42%
EBIT Next 5 Year
N/A
HARPOON THERAPEUTICS INC / HARP Forecast FAQ
What is the next earnings date for HARP stock?
HARPOON THERAPEUTICS INC (HARP) will report earnings on 2024-03-25, after the market close.
What are the consensus estimates for HARP stock next earnings?
The consensus EPS estimate for the next earnings of HARPOON THERAPEUTICS INC (HARP) is -0.65 USD and the consensus revenue estimate is 5.71M USD.
Can you provide the consensus rating for HARPOON THERAPEUTICS INC stock?
The consensus rating for HARPOON THERAPEUTICS INC (HARP) is 72 / 100 . This indicates that analysts generally have a positive outlook on the stock.